Q-omics provides the consensus-scored IL3RA profile across patient tissues and cancer cell-line models. IL3RA expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IL3RA is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, IL3RA RNA expression shows 15,912 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where IL3RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL3RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL3RA survival associations across molecular data types. IL3RA RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL3RA RNA expression–survival associations across cancer types. High IL3RA expression shows unfavorable associations in KIRP, LUSC and ACC, but favorable associations in HNSC, SKCM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IL3RA RNA expression.
This table summarizes IL3RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL3RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL3RA shows lower tumor expression in LUAD, LUSC, UCEC and BLCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher IL3RA RNA expression in tumor versus normal tissue (log2 FC = +1.840, t-test p < 0.001).
This table shows molecular features associated with IL3RA in patient tissues and cancer cell lines. In patient samples, IL3RA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL3RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
